(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...

Glucotrack (GCTK) will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery ...

Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.

Continuous Blood Glucose Monitor will be integrated with automated insulin delivery system for major EU diabetes studyRUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq ...

Glucotrack, Inc. announced that it will present safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system at the 2025 International ...

(RTTNews) - Glucotrack, Inc. (GCTK), Wednesday, announced the results from its first-in-human trial of its continuous blood glucose monitoring or CBGM system, which will be presented at the 2025 ...

RUTHERFORD, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people ...

RUTHERFORD, N.J. and STOCKHOLM, April 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel ...

RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the ...

Glucotrack's Continuous Blood Glucose Monitor (CBGM) will provide real-time glucose readings to drive insulin delivery decisions for the bionic pancreas system. “We are committed to the goal of ...